Vivlodex Now Available for Osteoarthritis Pain

Vivlodex was first approved by the FDA last October
Vivlodex was first approved by the FDA last October

Iroko announced that Vivlodex (meloxicam) capsules are now available for the management of osteoarthritis (OA) pain. It was initially approved by the Food and Drug Administration (FDA) in October 2015.

Vivlodex utilizes SoluMatrix technology, which contains meloxicam as submicron particles that are about 10 times smaller than their original size. This reduction in particle size allows for a greater surface area, leading to faster dissolution and absorption. This results in the dosage strengths being  33% lower than than currently available oral meloxicam products. 

RELATED: Vivlodex Approved for Osteoarthritis Pain

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties. Its mechanism of action is not completely understood. However, because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

Vivlodex is available as 5mg and 10mg strength capsules in 30-  and 90-count bottles.

For more information call (877) 757-0676 or visit Vivlodex.com.

Loading links....